Oragenics appoints Dr. William Peacock as Chief Clinical Officer for Phase II concussion trial

ORAGENICS INC

Appointed Dr. William 'Frank' Peacock as Chief Clinical Officer effective May 22, 2024.
Dr. Peacock will oversee upcoming Phase II trial of ONP-002 for concussion in emergency departments.
Dr. Peacock is Vice Chair for Emergency Medicine Research at Baylor College of Medicine.
ONP-002, a new chemical entity delivered intranasally, showed safety in Phase I; Phase II planned.
Concussion is an unmet need with ~69M cases annually; post-concussion syndrome occurs in up to 20% of patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.